Home › NDC Lookup › Ingredients › Progesterone › 55566-6500-08
ENDOMETRIN Progesterone 100 mg Insert, 21-count — NDC 55566-6500-08 package photo
Label image from the product's FDA listing (DailyMed) — may show a different pack size or an older label revision.

ENDOMETRIN Progesterone 100 mg Insert, 21-count — NDC 55566-6500-8 (Billing 55566-6500-08)

by Ferring Pharmaceuticals Inc. · 1 CARTON in 1 CARTON / 21 BLISTER PACK in 1 CARTON / 1 INSERT in 1 BLISTER PACK

This is a package of 21 inserts of ENDOMETRIN Progesterone 100 mg Insert from Ferring Pharmaceuticals Inc., marketed since Jun 2007 and currently FDA-listed.

NDC 55566-6500-08
🏷️ FDA NDC (as labeled) 55566-6500-8 billing pads the package segment with a zero
This package
Contains21-count Pack sizes2 compare ↓
Product page 55566-6500-03 Also comes in: 21 inserts 55566-6500-3
Rx only Brand On market Non-controlled ⇄ Compare with another NDC
🗂️ FDA directory synced Oct 1, 2026 · this listing last changed Aug 20, 2026 · sources: openFDA · FDA label (DailyMed) · FDA Orange & Purple Book · First Databank · CMS NADAC, ASP, Medicare & Medicaid · RxNorm
📋 All sources & update times →

This page is curated, coded, and maintained by

Compiled from public FDA, CMS, DailyMed, NADAC, and related drug data sources. Editorial policy

NDC database record

One package, one record: these facts belong to NDC 55566-6500-8 alone.

Record
FDA NDC Directory package listing · Human prescription drug
Code segments
55566 labeler · 6500 product · 8 package
Package marketed since
Jun 21, 2007
Sample package
Yes — professional sample, not for sale
Listing certified through
Dec 31, 2027
Barcode (UPC-A, from the NDC)
3 5556665008 5
FDA record last changed
Aug 20, 2026
⚠️
Other active recalls for Progesterone (different manufacturers) — 2 · tap to view
These affect other manufacturers’ products for the same ingredient — not necessarily the exact NDC on this page.
Class II · Dec 27, 2024 — Presence of Particulate Matter: A market complaint was received of a glass piece in the vial. (Eugia US LLC) · FDA recall D-0186-2025
Class II · Jul 26, 2024 — Presence of Particulate Matter: Complaint received of a glass particle in the vial. (Eugia US LLC) · FDA recall D-0624-2024
Each entry is an official FDA enforcement report — look up any recall number in the FDA recall database ↗

Identity & classification

Regulatory identifiers FDA, NLM and CMS codes for this package

FDA NDC (as labeled) 55566-6500-8
Product NDC 55566-6500
11-digit billing NDC 55566650008
RxCUI 725094, 725098
UNII 4G7DS2Q64Y
Application # NDA022057
SPL Set ID 2ba50fa9-b349-40cb-9a4b-1af8faa4ec09
Established class (EPC) Progesterone
Chemical class Progesterone
DEA schedule Non-controlled
Marketing category NDA
Marketing status On market
FDA listing status Listed (active directory)
Marketing start 2007-06-21
Route VAGINAL
Dosage form INSERT
Substance PROGESTERONE
TE code (Orange Book) AB · RLD · RS

Drug-database identifiers Medi-Span GPI and First Databank GCN / HICL / AHFS classification

GCN Seq No 062815
GCN 98586
HICL code 020653
Ingredient (HICL) Progesterone, Micronized
HIC1 code P
Therapeutic class — broad (HIC1) Endocrine System
HIC2 code P0
Therapeutic class — intermediate (HIC2) Ovulation Stimulants/Pregnancy Facilitators
HIC3 code P0C
Therapeutic class — specific (HIC3) Pregnancy Facilitating/Maintaining Agent,Hormonal
AHFS code 68:32.00.00
AHFS class Progestins
FDB label name ENDOMETRIN 100 MG VAG INSERT
FDB brand name Endometrin
Legend status F — Federal legend — prescription drug or device
Quick answers
  • GSN (GCN sequence number): 062815
  • GCN: 98586
  • HICL (First Databank): 020653
  • AHFS class code: 68:32.00.00
  • RxCUI (RxNorm): 725094
Why two NDCs? The FDA registers this code as 55566-6500-8 — a 5-4-1 layout, and that's what's printed on the package and shown on DailyMed. For insurance claims, every NDC is standardized to a uniform 11-digit 5-4-2 format by adding a zero to the package segment → 55566-6500-08. Same drug, same package — only the format differs.
Where does this data come from?
Identifiers from the FDA openFDA NDC Directory and Structured Product Labeling; RxCUI from RxNorm (NLM); GPI from Medi-Span; GCN / HIC / AHFS / legend from First Databank.

RxNorm drug class

This medicine belongs to the Progesterone class.

Pharmacologic class Progesterone
Drug family (ATC) Pregnen (4) derivatives
Where does this data come from?
Therapeutic classes from RxNorm RxClass (U.S. National Library of Medicine) — Established Pharmacologic Class (FDA), ATC drug family (WHO) and mechanism of action, matched by this product’s RxCUI.

Clinical

Label name ENDOMETRIN 100 MG VAG INSERT Ingredient Progesterone, Micronized
📗 Our plain-language guide HelloPharmacist
  • It depends on the product. Vaginal forms support pregnancy in fertility treatment. Capsules prevent overgrowth of the uterine lining in postmenopausal women taking estrogen, and tr...
  • Take them at bedtime, as your prescriber directs. If they're hard to swallow, use a full glass of water while standing. Food can increase how much your body absorbs.
  • With capsules taken alongside estrogen, headache, breast tenderness, joint pain, dizziness, and bloating were common. Vaginal discharge and nausea were reported too. Tell your doct...
  • Get help for chest pain, sudden weakness or trouble speaking, leg swelling, or sudden shortness of breath. These can be signs of a stroke, heart attack, or blood clot. Sudden visio...
📖 Read our full Progesterone guide →
Where does this data come from?
Plain-language summary from MedlinePlus (U.S. National Library of Medicine); supplement & herbal interactions and nutrient depletion data from the Natural Medicines database; our full guide is HelloPharmacist editorial content.

Pricing

A drug doesn't have one price. Each row is a different public payment system, and none is what you'd pay at the counter — that depends on your insurance. The ⓘ on each row explains what it measures.

Price systemPer eachPer package
Retail pharmacies payNADAC · weekly Not in the retail survey — common for institutional, discontinued, or low-volume packs.
Medicaid paysCMS SDUD · 12 mo No recent Medicaid claims on file for this NDC — rare and low-volume NDCs are suppressed in the public data.
Medicare drug plans payPart D · quarterly No Part D plan price is available for this NDC in our data.
ℹ️
No price is published for this exact package yet. CMS surveys NADAC per package size, so a different pack of the same drug often has one.
Try another pack size: 21 inserts
Where does this data come from?
NADAC (National Average Drug Acquisition Cost) is the CMS weekly pharmacy-acquisition-cost survey — what pharmacies pay. ASP (Average Sales Price) is the CMS Medicare Part B drug-payment file, published quarterly. Medicaid pays is computed by us from CMS State Drug Utilization Data (total reimbursed ÷ units, trailing 12 months) — gross of rebates and inclusive of dispensing fees, so it reflects what Medicaid paid, not an acquisition cost. Medicare drug plans pay is the median negotiated point-of-sale unit cost across plans listing this NDC in the CMS quarterly Prescription Drug Plan pricing files, before rebates. The VA pays is the federal contract price (FSS, and the statutory Big 4 ceiling where listed) from the VA National Acquisition Center pharmaceutical price file. All are free public government data; each measures a different payer, so the figures are not directly comparable.

Packaging — all sizes for this product

Package NDCDescription Per unit Per pack Marketing startMarketing endStatus
55566-6500-03 55566-6500-3 Main listing 1 CARTON in 1 CARTON / 21 BLISTER PACK in 1 CARTON / 1 INSERT in 1 BLISTER PACK $15.15 / ea $318.19 2007-06-21 — Active
55566-6500-08 You're viewing this 1 CARTON in 1 CARTON / 21 BLISTER PACK in 1 CARTON / 1 INSERT in 1 BLISTER PACK Sample — — 2007-06-21 — Active

This pack shows little to no recent Medicaid volume — a different pack size carries most fills. See all packs ↓

Pack size FAQ

What quantity is in this package?
This is a 21-count package — 1 carton in 1 carton / 21 blister pack in 1 carton / 1 insert in 1 blister pack.
How does this package differ from NDC 55566-6500-03?
Both are ENDOMETRIN Progesterone 100 mg Insert — the drug itself is identical. This page's package is the 21-count one, while NDC 55566-6500-03 is the 21 inserts package.
What NDC number is used to bill for this package of ENDOMETRIN Progesterone 100 mg Insert?
Use the 11-digit billing form listed in the identifiers section of this page. Pharmacy and medical claims use the 11-digit form; the FDA label may print a shorter form of the same code.

Prices are the latest CMS NADAC pharmacy acquisition cost per NDC; per-pack figures are per-unit × pack quantity, shown only when the pack is denominated in the same measure NADAC prices.

Therapeutic equivalents

ProductLabelerPackNADAC/unitTEStatusPrice vs. this
Progesterone Vaginal Inserts 100 mg 68462-0175-33 Glenmark 21 inserts $10.876 AB Availability likely —
Progesterone 100 mg 70095-0136-03 Sun 21 inserts $10.876 AB Availability likely —
Progesterone vaginal insert 100 mg 70700-0201-70 XIROMED, 21 inserts $10.876 AB Availability likely —
Endometrin 100 mgthis 55566-6500-08 Ferring 21 inserts — AB FDA listed —
About this product: this is the brand-name version. FDA-approved generic versions are listed, and recent pricing/market data suggests they may be available.
Where does this data come from?
Equivalents are other NDCs of the same ingredient, form and route from the openFDA NDC Directory, ranked least-expensive-first by NADAC. Therapeutic-equivalence (AB) ratings come from the FDA Orange Book; biologics use the FDA Purple Book for biosimilar & interchangeable status.

Availability & generic status

🏛️
2007
On the market since
Jun 2007
📍
2026
Currently FDA-listed
19 years listed
🔓
·
Generic versions listed
see equivalents
✅Generic appears available

FDA-approved generic versions are listed, and recent pricing/market data suggests they may be available — see Therapeutic equivalents.

Where does this data come from?
Patents and exclusivity from the FDA Orange Book (small-molecule drugs), refreshed from public FDA data. Generic launch timing is an estimate, not a guarantee.

What it looks like

Color white
ShapeOval
ImprintFPI;100
One label can cover several strengths, so colors may be combined — always confirm a loose pill against the dispensed prescription label or a pharmacist.
Where does this data come from?
Physical description (imprint, shape, color, scoring, coating) from this product’s FDA Structured Product Labeling (SPL), mirrored from DailyMed / openFDA.

Inactive Ingredients / Excipients

Inactive ingredients, also called excipients, are components of the drug product other than the active ingredient. They may include fillers, dyes, coatings, preservatives, flavors, or other formulation ingredients.

💡 Tap an ingredient (hover on desktop) to see what it is and why it’s used.

  • UNII 76A0JE0FKJ
    Adipic acid is an organic compound used in medicines as a buffer and pH regulator. It helps maintain the proper acidity level in the product to keep it stable and improve how the body absorbs the active ingredient.
  • UNII EWQ57Q8I5X
    Lactose monohydrate is a natural sugar derived from milk. It serves as a filler and binder in tablets and capsules, helping create the proper size, texture, and consistency of the medicine.
  • UNII 70097M6I30
    Magnesium stearate is a salt made from magnesium and stearic acid, a fatty substance. It's used in tablets and capsules as a lubricant and glidant to help ingredients flow smoothly during manufacturing and prevent sticking.
  • UNII U725QWY32X
    Povidone K30 is a synthetic polymer made from petroleum. It acts as a binder to hold tablet ingredients together and as a disintegrant to help the tablet break apart in the stomach so the medicine can be absorbed.
  • UNII ETJ7Z6XBU4
    Silicon dioxide is a naturally occurring mineral used as a glidant and anti-caking agent. It helps powder ingredients flow smoothly and prevents clumping during manufacturing and storage.
  • UNII 8MDF5V39QO
    A white powder form of baking soda that acts as a buffer and pH regulator in medicines. It helps maintain the right acid-base balance and may aid tablet disintegration.
  • UNII 368GB5141J
    A detergent and foaming agent derived from coconut or palm oil. In medications, it helps break down and mix oil and water-based ingredients, aids in tablet disintegration, and improves how the drug dissolves and spreads in the mouth or digestive system.
  • UNII O8232NY3SJ
    A plant-based carbohydrate derived from corn kernels. It acts as a filler to add bulk, a binder to hold ingredients together, and a disintegrant to help the tablet break apart in your stomach for absorption.

8 inactive ingredients listed in the exact product block matched to this NDC.

Where does this data come from?
Data sourced from official FDA Structured Product Labeling (SPL) via DailyMed — ingredient classCode="IACT" elements from the exact product block matched by this NDC. Label-section narrative from DailyMed / the openFDA label index is shown separately when available.

Inactive ingredient FAQ

Are inactive ingredients the same for every manufacturer?
No. Inactive ingredients can differ by manufacturer, dosage form, strength, and package / product version.
Why might an inactive ingredient be missing?
Some SPLs do not provide a complete structured inactive-ingredient list, and older or unusual labels may only include the information in narrative text.
Can inactive ingredients matter?
Yes. They can matter for allergies, intolerances, dyes, gluten / lactose concerns, preservatives, and formulation differences — but confirm with a pharmacist or the manufacturer when it’s clinically important.

Manufacturer & labeler

LabelerFerring Pharmaceuticals Inc.
Application holderFERRING PHARMACEUTICALS INC
FDA applicationNDA022057 (NDA)
Labeler code55566
First marketedJun 2007
Product typeHuman Prescription Drug
Portfolio17 products on file

More NDCs from Ferring Pharmaceuticals Inc. labeler code 55566

The labeler markets the product; the application holder owns the FDA approval. They’re often the same company but can differ (e.g. a repackager or an authorized generic). A mailing address / phone appears here when the manufacturer includes it in the product’s FDA label (not all do).
Where does this data come from?
Labeler, application holder and registered establishment from the FDA openFDA NDC Directory and Drugs@FDA; address/contact from the product’s FDA label.

Full prescribing information FDA SPL

The complete FDA label for this product — the official prescribing information, verbatim, section by section. Very long sections are excerpted here and marked; the full text is on DailyMed (linked in the sources below). Jump with a chip, search within the label, or expand everything.
🎯 Indications and Usage ⏱️ Dosage and Administration 💊 Dosage Forms and Strengths ⛔ Contraindications ⚠️ Warnings and Cautions 🤒 Adverse Reactions 🔄 Drug Interactions 👥 Use in Specific Populations 🤰 Pregnancy 🧒 Pediatric Use 🧓 Geriatric Use 🆘 Overdosage 🧬 Clinical Pharmacology 🧬 Mechanism of Action 📦 How Supplied / Storage and Handling 📋 Description 💬 Information for Patients 🧬 Pharmacokinetics 🧬 Pharmacodynamics 🔬 Clinical Studies 🧪 Nonclinical Toxicology 📄 Carcinogenesis, Mutagenesis, Impairment of Fertility 📄 Patient Package Insert 📄 Package Label / Principal Display Panel
🎯 Indications and Usage 91 words ▾

1 INDICATIONS AND USAGE ENDOMETRIN ® is indicated, as part of an Assisted Reproductive Technology (ART) treatment program, to support embryo implantation in infertile women less than 35 years of age by supplementation of corpus luteal function and to maintain pregnancy after implantation up to 10 weeks. ENDOMETRIN is a progesterone indicated, as part of an Assisted Reproductive Technology (ART) treatment program, to support embryo implantation in infertile women less than 35 years of age by supplementation of corpus luteal function and to maintain pregnancy after implantation up to 10 weeks.

⏱️ Dosage and Administration 95 words ▾

2 DOSAGE AND ADMINISTRATION The recommended ENDOMETRIN dose is 100 mg administered vaginally two or three times daily starting the day after oocyte retrieval and continuing for up to 10 weeks total duration. The recommended ENDOMETRIN dose is 100 mg administered vaginally two or three times daily starting the day after oocyte retrieval and continuing for up to 10 weeks total duration. ( 2 ) Efficacy in women 35 years of age and older has not been clearly established.

The appropriate dose of ENDOMETRIN in this age group has not been determined. ( 2 )

💊 Dosage Forms and Strengths 33 words ▾

3 DOSAGE FORMS AND STRENGTHS Vaginal insert: 100 mg - white to off-white oblong-shaped debossed with “FPI” on one side and “100” on the other side. Vaginal insert: 100 mg ( 3 )

⛔ Contraindications 153 words ▾

4 CONTRAINDICATIONS ENDOMETRIN is contraindicated in women with any of the following conditions: Previous hypersensitivity reactions to progesterone or any of the ingredients of ENDOMETRIN [ see Description ( 11 ) ] Abnormal vaginal bleeding that has an undiagnosed etiology Known missed abortion or ectopic pregnancy Hepatic adenoma, hepatocellular carcinoma, acute hepatitis, or severe (decompensated) cirrhosis Current diagnosis of, or history of, a hormone-sensitive malignancy (e.g., breast cancer) Active arterial or venous thromboembolism or severe thrombophlebitis, or a history of these events ENDOMETRIN is contraindicated in patients with ( 4 ): Previous hypersensitivity reactions to progesterone or any of the ingredients in ENDOMETRIN Abnormal vaginal bleeding that has an undiagnosed etiology Known missed abortion or ectopic pregnancy Hepatic adenoma, hepatocellular carcinoma, acute hepatitis, or severe (decompensated) cirrhosis Current diagnosis of, or history of, a hormone-sensitive malignancy (e.g., breast cancer) Active arterial or venous thromboembolism or severe thrombophlebitis, or a history of these events

⚠️ Warnings and Cautions 127 words ▾

5 WARNINGS AND PRECAUTIONS Cardiovascular or Cerebrovascular Disorders: Life-threatening arterial or venous thromboembolic disorders may occur during hormone treatment, including treatment with ENDOMETRIN. Discontinue ENDOMETRIN if any of these are suspected. ( 5.1 ) Depression: Closely observe ENDOMETRIN-treated women with a history of depression. Consider ENDOMETRIN discontinuation if symptoms worsen. (5.2)

5.1Cardiovascular or Cerebrovascular Disorders Life-threatening arterial or venous thromboembolic disorders may occur during hormone treatment, including treatment with ENDOMETRIN. The healthcare provider should be alert to earliest signs of myocardial infarction, cerebrovascular disorders, arterial or venous thromboembolism (venous thromboembolism or pulmonary embolism), thrombophlebitis, or retinal thrombosis. ENDOMETRIN should be discontinued if any of these are suspected.

5.2Depression ENDOMETRIN-treated women with a history of depression should be closely observed. Consider ENDOMETRIN discontinuation if symptoms worsen.

🤒 Adverse Reactions ~1 min read ▾

6 ADVERSE REACTIONS The most common adverse reactions reported (greater than 2%) were post-oocyte retrieval pain, abdominal pain, nausea, and ovarian hyperstimulation syndrome. ( 6 ) To report SUSPECTED ADVERSE REACTIONS, contact Ferring Pharmaceuticals Inc. at 1-888-FERRING (1-888-337-7464) or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch .

6.1Clinical Studies Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. The safety data reflect exposure to ENDOMETRIN in 808 infertile women in a single Assisted Reproductive Technology 10 week clinical study conducted in the U.S. [see Clinical Studies (14)]. ENDOMETRIN was studied at vaginally administered doses of 100 mg twice daily and 100 mg three times daily for 10 weeks and compared to a vaginally administered active comparator.

The adverse reactions that occurred at a rate greater than or equal to 2% in either ENDOMETRIN group are summarized in Table 1. Other less common reported adverse reactions in ENDOMETRIN-treated women included vaginal irritation, itching, burning, discomfort, urticaria, and peripheral edema. Table 1: Number and Frequency of Reported Adverse Reactions in Infertile Women Treated with ENDOMETRIN in an Assisted Reproductive Technology Study ENDOMETRIN 100 mg twice daily (N=404) ENDOMETRIN 100 mg three times daily (N=404) Post-oocyte retrieval pain 115 (28%) 102 (25%) Abdominal pain 50 (12%) 50 (12%) Nausea 32 (8%) 29 (7%) Ovarian hyperstimulation syndrome 30 (7%) 27 (7%) Abdominal distension 18 (4%) 17 (4%) Headache 15 (4%) 13 (3%) Uterine spasm 15 (4%) 11 (3%) Vaginal bleeding 13 (3%) 14 (3%) Vomiting 13 (3%) 9 (2%) Urinary tract infection 9 (2%) 4 (1%) Constipation 9 (2%) 14 (3%) Fatigue 7 (2%) 12 (3%) Adverse Reactions from Other Progesterone Products Adverse reactions from other progesterone products included breast tenderness, bloating, mood swings, irritability, and drowsiness.

🔄 Drug Interactions 105 words ▾

7 DRUG INTERACTIONS Drugs known to induce the hepatic cytochrome-P450-3A4 system may increase the elimination of progesterone, lower progesterone exposure in ENDOMETRIN-treated women, and reduce the efficacy of ENDOMETRIN. The effect of concomitant vaginal products on the exposure of progesterone from ENDOMETRIN has not been assessed. ENDOMETRIN is not recommended for use with other vaginal products (such as antifungal products) as this may alter progesterone release and absorption from the ENDOMETRIN vaginal insert.

CYP3A4 Inducers: May increase the elimination of progesterone and may reduce the efficacy of ENDOMETRIN. ( 7 ) Other Vaginal Products: Avoid use of ENDOMETRIN with other vaginal products. ( 7 )

👥 Use in Specific Populations ~3 min read ▾

8 USE IN SPECIFIC POPULATIONS Pediatric Use: ENDOMETRIN is not for pediatric use. ( 8.4 ) Geriatric Use: ENDOMETRIN is not for use in women 65 years of age and older. ( 8.5 )

8.1Pregnancy Risk Summary ENDOMETRIN is indicated, as part of an Assisted Reproductive Technology (ART) treatment program, to support embryo implantation in infertile women less than 35 years of age by supplementation of corpus luteal function and to maintain pregnancy after implantation up to 10 weeks. Maternal risks of ENDOMETRIN use during pregnancy are discussed throughout the labeling. In the US general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively.

Data Human Data: In one clinical study [see Clinical Studies (14)], ENDOMETRIN was vaginally administered to support embryo implantation during the first trimester of pregnancy and to maintain clinical pregnancy through week 10 of pregnancy when the placenta takes over production of progesterone. The live birth outcomes of these pregnancies were as follows: • Among the 404 women treated with ENDOMETRIN twice daily, 143 (35%) women had live births consisting of 85 (59%) singletons, 56 (39%) twins, and 2 (1%) triplets.

In this treatment group, 13 (3%) women had a spontaneous abortion, 1 (0.2%) woman had an ectopic pregnancy, and neonatal birth defects were reported in 7 infants (3% based on 203 live births). • Among the 404 women treated with ENDOMETRIN three times daily, 155 (38%) women had live births consisting of 91 (59%) singletons, 60 (39%) twins, and 4 (3%) triplets. In this treatment group, 22 (5%) women had a spontaneous abortion, 4 (1%) women had an ectopic pregnancy, and neonatal birth defects were reported in 7 infants (3% based on 223 live births).

Birth defects reported in the ENDOMETRIN: Twice daily group included one neonate with a cleft palate and intrauterine growth retardation, one with spina bifida, three with congenital heart defects, one with an umbilical hernia, and one with an intestinal anomaly. Three times daily group included one neonate with an esophageal fistula, one with hypospadias and an underdeveloped right ear, one with Down Syndrome and an atrial septal defect, one with congenital heart anomalies, one with DiGeorge’s syndrome, one fetus with a hand deformity, and one with cleft palate.

For additional information on the pharmacology of ENDOMETRIN and pregnancy outcome information [see Clinical Pharmacology (12) and Clinical Studies (14) ] .

8.2Lactation Risk Summary Detectable amounts of progesterone have been identified in the milk of nursing mothers. The effect of this on the nursing infant has not been determined. A published study reported no adverse effects of progesterone on milk production or infant growth during the first postpartum year.

The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for ENDOMETRIN and any potential adverse effects on the breastfed child from ENDOMETRIN or from the underlying maternal condition.

8.4Pediatric Use The safety and effectiveness of ENDOMETRIN in pediatric patients have not been established.

8.5Geriatric Use Clinical studies of ENDOMETRIN did not include women 65 years of age and older. ENDOMETRIN is not indicated for use in this population.

8.6Body Mass Index The safety and efficacy of ENDOMETRIN in women with a body mass index (BMI) >34 kg/m 2 has not been studied.

8.7Hepatic Impairment ENDOMETRIN is contraindicated in women with hepatic adenoma, hepatocellular carcinoma, acute hepatitis, or severe (decompensated) cirrhosis.

🤰 Pregnancy ~2 min read ▾

8.1Pregnancy Risk Summary ENDOMETRIN is indicated, as part of an Assisted Reproductive Technology (ART) treatment program, to support embryo implantation in infertile women less than 35 years of age by supplementation of corpus luteal function and to maintain pregnancy after implantation up to 10 weeks. Maternal risks of ENDOMETRIN use during pregnancy are discussed throughout the labeling. In the US general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively.

Data Human Data: In one clinical study [see Clinical Studies (14)], ENDOMETRIN was vaginally administered to support embryo implantation during the first trimester of pregnancy and to maintain clinical pregnancy through week 10 of pregnancy when the placenta takes over production of progesterone. The live birth outcomes of these pregnancies were as follows: • Among the 404 women treated with ENDOMETRIN twice daily, 143 (35%) women had live births consisting of 85 (59%) singletons, 56 (39%) twins, and 2 (1%) triplets.

In this treatment group, 13 (3%) women had a spontaneous abortion, 1 (0.2%) woman had an ectopic pregnancy, and neonatal birth defects were reported in 7 infants (3% based on 203 live births). • Among the 404 women treated with ENDOMETRIN three times daily, 155 (38%) women had live births consisting of 91 (59%) singletons, 60 (39%) twins, and 4 (3%) triplets. In this treatment group, 22 (5%) women had a spontaneous abortion, 4 (1%) women had an ectopic pregnancy, and neonatal birth defects were reported in 7 infants (3% based on 223 live births).

Birth defects reported in the ENDOMETRIN: Twice daily group included one neonate with a cleft palate and intrauterine growth retardation, one with spina bifida, three with congenital heart defects, one with an umbilical hernia, and one with an intestinal anomaly. Three times daily group included one neonate with an esophageal fistula, one with hypospadias and an underdeveloped right ear, one with Down Syndrome and an atrial septal defect, one with congenital heart anomalies, one with DiGeorge’s syndrome, one fetus with a hand deformity, and one with cleft palate.

For additional information on the pharmacology of ENDOMETRIN and pregnancy outcome information [see Clinical Pharmacology (12) and Clinical Studies (14) ] .

🧒 Pediatric Use 16 words ▾

8.4Pediatric Use The safety and effectiveness of ENDOMETRIN in pediatric patients have not been established.

🧓 Geriatric Use 26 words ▾

8.5Geriatric Use Clinical studies of ENDOMETRIN did not include women 65 years of age and older. ENDOMETRIN is not indicated for use in this population.

🆘 Overdosage 41 words ▾

10 OVERDOSAGE Treatment of overdosage consists of discontinuation of ENDOMETRIN together with institution of appropriate symptomatic and supportive care. If an overdose of ENDOMETRIN occurs, consider contacting the Poison Help line (1-800-222-1222) or a medical toxicologist for additional overdose management recommendations.

🧬 Clinical Pharmacology ~2 min read ▾

12 CLINICAL PHARMACOLOGY

12.1Mechanism of Action Progesterone is a naturally occurring steroid that is secreted by the ovary, placenta, and adrenal gland. In the presence of adequate estrogen, progesterone transforms a proliferative endometrium into a secretory endometrium. Progesterone is necessary to increase endometrial receptivity for implantation of an embryo. Once an embryo is implanted, progesterone acts to maintain a pregnancy.

12.2Pharmacodynamics The exposure-response relationship and time course of pharmacodynamic response for the safety and effectiveness of ENDOMETRIN have not been fully characterized.

12.3Pharmacokinetics Absorption Progesterone serum concentrations increased following the administration of the ENDOMETRIN vaginal insert in 12 healthy premenopausal females. After 5 days of dosing, steady-state progesterone concentrations were attained within approximately 1 day after initiation of ENDOMETRIN treatment. Both ENDOMETRIN dosing regimens provided average serum progesterone concentrations that exceeded 10 ng/mL on Day 5.

The pharmacokinetic results are summarized in Table 2. Table 2: Mean (±Standard Deviation) Serum Progesterone Pharmacokinetic Parameters after ENDOMETRIN Vaginal Administration Pharmacokinetic Parameter (unit) ENDOMETRIN 100 mg twice daily (N=6) ENDOMETRIN 100 mg three times daily (N=6) One Day of Dosing C max (ng/mL) 17 ± 6.5 19.8 ±

7.2T max (hr) 24 ± 0 17.3 ±

7.4AUC 0-24 (ng•hr/mL) 217 ± 113 284 ± 143 Day 5 of Multiple Dosing C max (ng/mL) 18.5 ± 5.5 24.1 ±

5.6T max (hr) 18 ± 9.4 18 ±

9.4C min (ng/mL) 8.9 ± 4.5 10.9 ±

6.7C avg (ng/ml) 14 ± 4.8 15.9 ±

4.3AUC 0-24 (ng•hr/mL) 327 ± 127 436 ± 106 C max Maximum progesterone serum concentration. T max Time to maximum progesterone serum concentration. C avg Average progesterone serum concentration.

AUC 0-24 Area under the drug concentration versus time curve from 0-24 hours post dose. C min Minimum progesterone serum concentration. Distribution Progesterone is approximately 96% to 99% bound to serum proteins, primarily to serum albumin and corticosteroid binding globulin.

Elimination Metabolism: Progesterone is metabolized primarily by the liver, largely to pregnanediols and pregnanolones. Pregnanediols and pregnanolones are conjugated in the liver to glucuronide and sulfate metabolites. Progesterone metabolites that are excreted in the bile may be deconjugated and may be further metabolized in the gut via reduction, dehydroxylation, and epimerization.

Excretion: Progesterone undergoes renal and biliary elimination. Following injection of labeled progesterone, 50-60% of the excretion of metabolites occurs via the kidney; approximately 10% occurs via the bile and feces. Overall recovery of the labeled material accounts for 70% of an administered dose.

Only a small portion of unchanged progesterone is excreted in the bile .

🧬 Mechanism of Action 58 words ▾

12.1Mechanism of Action Progesterone is a naturally occurring steroid that is secreted by the ovary, placenta, and adrenal gland. In the presence of adequate estrogen, progesterone transforms a proliferative endometrium into a secretory endometrium. Progesterone is necessary to increase endometrial receptivity for implantation of an embryo. Once an embryo is implanted, progesterone acts to maintain a pregnancy.

📦 How Supplied / Storage and Handling 74 words ▾

16 HOW SUPPLIED/STORAGE AND HANDLING Each ENDOMETRIN vaginal insert is a white to off-white oblong-shaped debossed with “FPI” on one side and “100” on the other side. Each vaginal insert, 100 mg, is packed individually in a sealed foil pouch. These pouches are available in cartons packed: 21 vaginal inserts with 21 disposable vaginal applicators (NDC 55566-6500-3) Store at 20 - 25˚C (68 - 77˚F); excursions permitted between 15 - 30°C (59 - 86°F).

📋 Description 107 words ▾

11 DESCRIPTION ENDOMETRIN (progesterone) vaginal insert contains micronized progesterone. ENDOMETRIN is supplied with polyethylene vaginal applicators. The active ingredient, progesterone, is present (100 mg) along with inactive ingredients.

The chemical name for progesterone is pregn-4-ene-3,20-dione, its empirical formula is C 21 H 30 O 2 , its molecular weight is 314.5. Progesterone exists in two polymorphic forms. The form used in ENDOMETRIN, the alpha-form, has a melting point of 127-131°C.

The structural formula is: Each ENDOMETRIN vaginal insert delivers 100 mg of progesterone in a base containing lactose monohydrate, polyvinylpyrrolidone, adipic acid, sodium bicarbonate, sodium lauryl sulfate, magnesium stearate, pregelatinized starch, and colloidal silicon dioxide. Chemical Structure

💬 Information for Patients 89 words ▾

17 PATIENT COUNSELING INFORMATION Advise the patient to read the FDA-Approved patient labeling (Patient Information). Vaginal Bleeding Inform patients of the importance of reporting irregular vaginal bleeding to their health care provider as soon as possible. Common Adverse Reactions with Progesterone Inform patients of the possible adverse reactions of ENDOMETRIN therapy such as headaches, breast tenderness, bloating, mood swings, irritability, and drowsiness.

Coadministration of Other Vaginal Products Inform patients that ENDOMETRIN is not recommended for use with other vaginal products. Manufactured for: Ferring Pharmaceuticals Inc Parsippany, NJ 07054 XXXXXXXXXX

🧬 Pharmacokinetics ~2 min read ▾

12.3Pharmacokinetics Absorption Progesterone serum concentrations increased following the administration of the ENDOMETRIN vaginal insert in 12 healthy premenopausal females. After 5 days of dosing, steady-state progesterone concentrations were attained within approximately 1 day after initiation of ENDOMETRIN treatment. Both ENDOMETRIN dosing regimens provided average serum progesterone concentrations that exceeded 10 ng/mL on Day 5.

The pharmacokinetic results are summarized in Table 2. Table 2: Mean (±Standard Deviation) Serum Progesterone Pharmacokinetic Parameters after ENDOMETRIN Vaginal Administration Pharmacokinetic Parameter (unit) ENDOMETRIN 100 mg twice daily (N=6) ENDOMETRIN 100 mg three times daily (N=6) One Day of Dosing C max (ng/mL) 17 ± 6.5 19.8 ±

7.2T max (hr) 24 ± 0 17.3 ±

7.4AUC 0-24 (ng•hr/mL) 217 ± 113 284 ± 143 Day 5 of Multiple Dosing C max (ng/mL) 18.5 ± 5.5 24.1 ±

5.6T max (hr) 18 ± 9.4 18 ±

9.4C min (ng/mL) 8.9 ± 4.5 10.9 ±

6.7C avg (ng/ml) 14 ± 4.8 15.9 ±

4.3AUC 0-24 (ng•hr/mL) 327 ± 127 436 ± 106 C max Maximum progesterone serum concentration. T max Time to maximum progesterone serum concentration. C avg Average progesterone serum concentration.

AUC 0-24 Area under the drug concentration versus time curve from 0-24 hours post dose. C min Minimum progesterone serum concentration. Distribution Progesterone is approximately 96% to 99% bound to serum proteins, primarily to serum albumin and corticosteroid binding globulin.

Elimination Metabolism: Progesterone is metabolized primarily by the liver, largely to pregnanediols and pregnanolones. Pregnanediols and pregnanolones are conjugated in the liver to glucuronide and sulfate metabolites. Progesterone metabolites that are excreted in the bile may be deconjugated and may be further metabolized in the gut via reduction, dehydroxylation, and epimerization.

Excretion: Progesterone undergoes renal and biliary elimination. Following injection of labeled progesterone, 50-60% of the excretion of metabolites occurs via the kidney; approximately 10% occurs via the bile and feces. Overall recovery of the labeled material accounts for 70% of an administered dose.

Only a small portion of unchanged progesterone is excreted in the bile .

🧬 Pharmacodynamics 23 words ▾

12.2Pharmacodynamics The exposure-response relationship and time course of pharmacodynamic response for the safety and effectiveness of ENDOMETRIN have not been fully characterized.

🔬 Clinical Studies ~3 min read ▾

14 CLINICAL STUDIES A randomized, open-label, active-controlled study evaluated the efficacy of two different daily dosing regimens of ENDOMETRIN (100 mg twice daily administered vaginally or 100 mg three times daily administered vaginally for 10 weeks) and a vaginally administered active comparator to support embryo implantation (as part of an Assisted Reproductive Technology (ART) treatment program) in infertile women less than 35 years of age by supplementation of corpus luteal function and to maintain pregnancy after implantation up to 10 weeks.

Efficacy of the two ENDOMETRIN regimens was assessed by an endpoint of pregnancies, defined as the presence of at least one fetal heartbeat seen on ultrasound at 6 weeks post-embryo transfer. The study included 808 infertile women who were treated with one of the two ENDOMETRIN dosing regimens (75% White; 10% Hispanic, 5% Black, 5% Asian, and 5% other races) between 19 and 42 years of age (mean age 33 years old) who had a body mass index <34 kg/m 2 at screening. The ongoing pregnancy rates for infertile women treated with both dosing regimens of ENDOMETRIN were non-inferior (lower bounds of the 95% confidence interval of the difference between the two ENDOMETRIN dosing regimens and the active comparator excluded a difference greater than 10%) to the pregnancy rate for infertile women treated with the active comparator.

The results of ENDOMETRIN treatment groups (but not the active comparator group) in this study are shown in Table 3. Table 3: Pregnancy Rates* in Infertile Women Who Received ENDOMETRIN to Support Embryo Implantation by Supplementation of Corpus Luteal Function as Part of an ART Program ENDOMETRIN 100 mg twice daily for 10 weeks ENDOMETRIN 100 mg three times daily for 10 weeks Number of subjects 404 404 Pregnancy: n (%) 156 (39%) 171 (42%) 95% Confidence Interval of pregnancy rate [33.8, 43.6] [37.5, 47.3] Pregnancy rate percentage difference between each ENDOMETRIN treatment group and the active comparator -3.6% 0.1% 95% Confidence Interval for difference vs active comparator [-10.3, 3.2] [-6.7, 6.9] *Pregnancy was defined as the presence of at least one fetal heartbeat seen on ultrasound at 6 weeks post-embryo transfer.

Subjects participating in the study were stratified at randomization by age and ovarian reserve (as measured by serum FSH levels). The pregnancy rates for these subgroups in the ENDOMETRIN treatment groups (but not the active comparator group) are shown in Table 4. In subjects: Under the age of 35 or with serum FSH levels less than 10 IU/L, results from both ENDOMETRIN dosing regimens were non-inferior to the results from the active comparator with respect to pregnancy rates.

Age 35 and older and in subjects with serum FSH levels between 10 and 15 IU/L, the results with respect to ongoing pregnancy rates for both ENDOMETRIN dosing regimens did not reach the criteria for non-inferiority. Subjects who became pregnant received study medication for a total of 10 weeks. Patients over 34 kg/m 2 were not studied; thus, the efficacy of ENDOMETRIN in these patients is unknown.

Table 4: Pregnancy Rates in Age- and Ovarian Reserve-Defined Subgroups Who Received ENDOMETRIN for Luteal Supplementation and Early Pregnancy While in an ART Program ENDOMETRIN 100 mg twice daily ENDOMETRIN 100 mg three times daily Subjects age < 35 years (N) Pregnancy: n (%) Pregnancy rate percentage difference between ENDOMETRIN and the active comparator 95% Confidence Interval for difference vs. active comparator 247 111 (45%) 0.5% [-8.3, 9.3] 247 117 (47%) 2.9% [-5.9, 11.7] Subjects 35-42 years of age (N) Pregnancy: n (%) Pregnancy rate percentage difference between ENDOMETRIN and the active comparator 95% Confidence Interval for difference vs. active comparator 157 45 (28%) -10.1% [-20.3, 0.3] 157 54 (34%) -4.4% [-14.9, 6.3] Subjects with FSH < 10 IU/L (N) Ongoing pregnancy: n (%) Pregnancy rate percentage difference between ENDOMETRIN and the active comparator 95% Confidence Inte… [Excerpted — this section continues on DailyMed.]

🧪 Nonclinical Toxicology 39 words ▾

13 NONCLINICAL TOXICOLOGY

13.1Carcinogenesis, Mutagenesis, Impairment of Fertility Nonclinical toxicity studies to determine the potential of ENDOMETRIN to cause carcinogenicity or mutagenicity have not been performed. The effect of ENDOMETRIN on fertility has not been evaluated in animals.

📄 Carcinogenesis, Mutagenesis, Impairment of Fertility 36 words ▾

13.1Carcinogenesis, Mutagenesis, Impairment of Fertility Nonclinical toxicity studies to determine the potential of ENDOMETRIN to cause carcinogenicity or mutagenicity have not been performed. The effect of ENDOMETRIN on fertility has not been evaluated in animals.

📄 Patient Package Insert ~3 min read ▾

PATIENT INFORMATION ENDOMETRIN (en-doh-ME-trin) (progesterone) vaginal insert Read this Patient Information before you start using ENDOMETRIN and each time you get a refill. There may be new information. This information does not take the place of talking to your healthcare provider about your medical condition or treatment.

What is ENDOMETRIN? ENDOMETRIN is a prescription medicine vaginal insert that contains the hormone progesterone and is used to support embryo implantation in women less than 35 years of age while undergoing treatment for infertility (an Assisted Reproductive Technology (ART) program) and to maintain pregnancy for up to 10 weeks. It is not known if ENDOMETRIN is safe and effective in children.

Important: For Vaginal Use Only. Who should not use ENDOMETRIN? Do not use ENDOMETRIN if you: are allergic to progesterone or any of the ingredients in ENDOMETRIN.

See the end of this leaflet for a complete list of ingredients in ENDOMETRIN. have abnormal, undiagnosed vaginal bleeding. have a known missed abortion or ectopic pregnancy. currently have or have had certain liver problems. currently have or have had cancer that is hormone sensitivity such as breast cancer. currently have or have had blood clots. Before using ENDOMETRIN, tell your healthcare provider about all of your medical conditions, including if you: have a history of a heart attack, stroke (cerebrovascular disorders), or blood clots. have a history of depression. are currently using any other vaginal products (such as antifungal products). are pregnant. are breastfeeding or plan to breastfeed.

Talk to your healthcare provider about the best way to feed your baby while using ENDOMETRIN. Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. You should not use ENDOMETRIN while using other vaginal products.

Using ENDOMETRIN with certain other medicines may affect how ENDOMETRIN works. Know what medicines you take. Keep a list of them to show your healthcare provider and pharmacist when you get a new medicine.

How should I use ENDOMETRIN? Use ENDOMETRIN exactly as your healthcare provider tells you to. ENDOMETRIN is placed in your vagina 2 to 3 times a day for up to a total of 10 weeks.

Do not use any other vaginal products while using ENDOMETRIN. Follow the steps below: Unwrap the applicator. Do not use if the contents or packaging are visibly damaged.

Put one vaginal insert in the space provided at the end of the applicator. The insert should fit snugly and not fall out. Place applicator with the insert into the vagina while you are standing, sitting, or when lying on your back with your knees bent.

Gently place the thin end of the applicator well into the vagina. Push the plunger to release the insert. Remove the applicator and throw it away in the trash.

Other information for using ENDOMETRIN If you forget a dose of ENDOMETRIN, take the dose as soon as you remember, but do not use more than your daily dose. Call your doctor if you use too much ENDOMETRIN. What are the possible side effects of ENDOMETRIN?

ENDOMETRIN may cause serious side effects, including: Risk of heart attack, stroke, or blood clots. Your healthcare provider may stop ENDOMETRIN if you have signs of heart attack, stroke, or blood clots. Symptoms of heart attack or blood clots may include: pain in lower leg shortness of breath coughing up blood sudden blindness, partial or complete severe chest pain sudden severe headache, vomiting, dizziness, or fainting weakness in an arm or leg, or trouble speaking D epressed mood.

Your healthcare provider may stop ENDOMETRIN if symptoms of depressed mood worsen. The most common side effects of ENDOMETRIN include: abdominal pain nausea abdominal bloating constipation vomiting fatigue pelvic pain after surgery headache swollen ovaries uterine cramping vaginal bleeding Call your healthcare provider right away if you have irregular vaginal bleeding. Thes… [Excerpted — this section continues on DailyMed.]

📄 Package Label / Principal Display Panel 66 words ▾

PRINCIPAL DISPLAY PANEL - 100 mg Carton NDC 55566-6500-3 Endometrin ® (progesterone) Vaginal Insert 100mg Contents: 21 vaginal inserts with 21 disposable vaginal applicators Each insert contains 100 mg progesterone, USP FOR VAGINAL USE ONLY Rx only Usual Dosage: See enclosed package insert for dosage and complete Prescribing Information. This carton contains instructions intended for the patient. FERRING PHARMACEUTICALS PRINCIPAL DISPLAY PANEL - 100 mg Carton

Source: FDA Structured Product Labeling, mirrored from DailyMed / openFDA. Prefer the government’s original formatting? View this label on DailyMed ↗

Medicaid utilization by pack size

Medicaid (SDUD) totals over the four most recent reported quarters for every package size of this drug — handy when a specific package (e.g. a starter/titration pack) carries little or no Medicaid volume on its own.
1 insert55566-6500-03 1,098 Rx · $665,383
21 inserts this page55566-6500-08 No Medicaid data
Drug total (last 4 qtrs): 1,098 Rx · 47,961 units · $665,383 gross reimbursed
Tap a pack size to open its page. Source: CMS State Drug Utilization Data, last 4 quarters.

Medicare Part D spend CMS · PART D · 2025 (Q1-Q4)

Medicare Part D (outpatient prescription) spending for Endometrin — the program that covers self-administered drugs. 1 manufacturer.
⚠️ Drug-level data: CMS publishes Part D spending by drug, not by NDC — these figures combine every manufacturer, strength and package size sold under the name Endometrin. That’s a different level of aggregation than the Medicaid card above, which is specific to this exact 11-digit NDC (pack size included), so the two aren’t directly comparable.
Total Part D spend
$7.6K
Claims incl. refills
15
Beneficiaries
—
Spend / beneficiary
—
Spend / claim
$509.17
💵 About the dollar figures: spending is what Part D plans paid before confidential manufacturer rebates, so the program’s real net cost is lower. A blank patient count means fewer than 11 people — CMS hides counts that small to protect privacy. Source: CMS Medicare Quarterly Part D Spending by Drug (data.cms.gov), updated quarterly.

Reported adverse events (FAERS)

Read carefully: FAERS reports are voluntary and unverified. Counts are not incidence, do not establish causation, are subject to reporting bias, and cannot be used to compare one drug to another. Shown for signal context only. Reports for Progesterone — the ingredient across all brands.

Top reported reactions

Headache2,094
Fatigue1,795
Pain1,482
Nausea1,475
Rash984
Dizziness941
Foetal Exposure During Pregnancy899

Age at onset

Neonate238
Infant28
Child10
Adolescent22
Adult3,061
Elderly420

Reporter sex

22,803 reports
Male · 3%
Female · 96%
Unknown · 0%

Serious outcomes

Hospitalization3,651
Disabling658
Death504
Life-threatening440
Reports over time (by year) — tap or hover for the count & year
2019 2021 2023 2026 2,311 0
Most recent year is provisional (FAERS lags ~3 months).
Where does this data come from?
Adverse-event reports from the FDA Adverse Event Reporting System (FAERS) via openFDA. FAERS reports are voluntary and unverified — counts are not incidence and don’t establish causation.

About this NDC listing & data coverage

Finished prescription product
What data is (and isn’t) available for this NDC — tap to expand
NDC identity (package / product / labeler codes) ✓ Available
Labeler ✓ Available
Product & package description ✓ Available
Marketing category & status ✓ Available
Active ingredient / dosage form / route ✓ Available
FDA label (SPL via DailyMed) ✓ Available
Package photos ✓ Available
Inactive ingredients (structured) ✓ Available
NADAC pharmacy acquisition price (CMS) — Not published for this NDC CMS publishes NADAC only for NDCs reported in its retail-pharmacy survey.
Orange Book / therapeutic-equivalence data ✓ Available
HCPCS J-code billing crosswalk — Not published for this NDC Most self-administered / retail products have no J-code — that is normal.
Medicaid utilization (CMS SDUD) — Not published for this NDC CMS reports utilization only for NDCs with Medicaid claims above its privacy threshold.
“Not published” reflects what the public FDA / CMS / NLM sources provide for this exact package code — it is a property of the data feeds, not a judgment about the product.

Questions about this listing

Why is there no price listed?
The pricing shown on our NDC pages comes from CMS NADAC, a voluntary survey of retail community pharmacy invoices. CMS does not publish a NADAC for every NDC — packages outside the retail survey (institutional and hospital products, bulk packages, discontinued items, and many OTC items) may never receive one. A missing price reflects the survey's scope, not this product's actual cost, and does not mean the product is free or unavailable.
Is the NDC printed on the package the same as the 11-digit billing NDC?
Yes, they identify this exact package in different formats. The form printed on the packaging and shown on DailyMed is the one the FDA registered. Insurance claims use a fixed 11-digit 5-4-2 format, so the short segment is padded with a leading zero and the dashes are dropped. The Identity section at the top of this page lists each form of this code.
Is this package still being marketed?
Yes, per the latest FDA NDC Directory data on this page: this package is listed as actively marketed, with no marketing end date reported by Ferring Pharmaceuticals Inc.. Listing status can change — the directory data on this page refreshes weekly.
Does this product come in other package sizes?
Yes — the FDA directory lists 1 other package presentation of this same product, including 21 inserts (55566-6500-03). Each has its own NDC and its own page — see the package list near the top of this page.
Who lists this product with the FDA?
Ferring Pharmaceuticals Inc. is the labeler of record for this NDC — the company under whose FDA-assigned code the package is listed. The labeler may be the manufacturer itself or a distributor marketing the product under its own code.
Do I need a prescription for this product?
This NDC is listed with FDA as a prescription product, so it is dispensed under a prescriber's order. Your pharmacist can tell you whether any over-the-counter forms of the same medication exist.
This page identifies an FDA-listed package (the NDC) and reports public regulatory and pricing data about the listing. It is reference information, not a medical recommendation — talk to your pharmacist or prescriber about your own medication.
Where does this data come from?
Listing facts (marketing category, packager status, marketing dates) from the FDA openFDA NDC Directory; label availability from DailyMed; pricing coverage from CMS NADAC; equivalence scope from the FDA Orange Book.
← 55566-3000-00 · Ferring 55566-6800-01 · Ferring →
For educational and professional reference only — not medical advice. Pricing reflects published NADAC and CMS ASP (free public data) and may differ from your acquisition cost; always verify before billing or dispensing.